ICON plc has released findings from its 2025 global biotech survey, highlighting China's growing dominance in the sector and outlining key opportunities for Western biotech companies to remain competitive. The survey, which gathered insights from over 260 biotech professionals and venture capital executives worldwide, shows increased investment and R&D activity in the Asia-Pacific region, particularly China. Chinese biotech firms report high confidence in investment and product success, with less concern about geopolitical risks compared to global peers. While cardiovascular and oncology remain top focus areas in China, the global industry is shifting toward neurology, with cell therapies, microbiome therapies, and antibody-drug conjugates prominent across all regions. Funding challenges persist globally, with a notable rise in organizations seeking additional R&D funding and a shift towards innovative funding models. Talent shortages are also emerging as a significant concern, especially in the Asia-Pacific region. The report underscores the importance of adaptability and innovation for biotechs facing financial and operational pressures in a rapidly evolving global landscape.